{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-222808","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2026-05-14T11:32:05+00:00","discovered_at":"2026-05-14T11:35:00.255655+00:00","generated_at":"2026-05-14T11:37:03.009432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Karyopharm Q1 revenue $35.1M, net loss $22.4M; Phase 3 endometrial trial enrollment complete","bullets":["U.S. XPOVIO net product revenue $29.2M (up from $21.1M YoY) on lower gross-to-net adjustments.","Net loss $22.4M ($1.02 basic loss per share) vs $23.5M loss in Q1 2025.","Cash $91.2M as of Mar 31, 2026; expects liquidity to fund operations into late Q3 2026.","Completed Phase 3 XPORT-EC-042 enrollment in endometrial cancer; topline data expected mid-2026.","Phase 3 SENTRY myelofibrosis results accepted for late-breaking oral at ASCO on June 2."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-222808","json":"https://secwatch.observer/filing/0001193125-26-222808.json","markdown":"https://secwatch.observer/filing/0001193125-26-222808.md","text":"https://secwatch.observer/filing/0001193125-26-222808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526222808/0001193125-26-222808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526222808/kpti-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:37:03.009432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}